Source comparison
Comparison: BPC-157 MK-677 Protocol vs Alternatives
Mechanism Dual pathway: local angiogenesis + systemic GH/IGF-1 Direct GH replacement Localised VEGF/FGF upregulation only BPC-157 + MK-677 synergises complementary repair mechanisms without suppressing endogenous hormones Cost (monthly) Approximately 120–180 (
This comparison does not assign a generated winner or score.
- Mechanism
- Dual pathway: local angiogenesis + systemic GH/IGF-1
- Direct GH replacement
- Localised VEGF/FGF upregulation only
- BPC-157 + MK-677 synergises complementary repair mechanisms without suppressing endogenous hormones
- Cost (monthly)
- Approximately 120–180 (peptides vary by supplier)
- 600–1,200+ (prescription GH)
- 60–90 (BPC-157 alone)
- Stack is 2–3× cost of BPC-157 alone but 70–85% cheaper than prescription GH with comparable IGF-1 elevation
- Administration
- Subcutaneous BPC-157 2×/day + oral MK-677 1×/night
- Daily subcutaneous GH injections
- Subcutaneous BPC-157 2×/day
- Oral MK-677 component simplifies compliance versus multi-injection protocols
- Endocrine Impact
- MK-677 preserves pulsatile GH; no negative feedback
- Suppresses endogenous GH production
- Negligible hormonal effect
- Stack maintains physiological GH patterns; exogenous GH shuts down natural secretion
- Healing Timeline
- 8–12 weeks for chronic injuries
- 6–10 weeks (faster initial response)
- 10–14 weeks for chronic injuries
- Exogenous GH shows quicker short-term gains but higher long-term risk; stack balances efficacy with safety
- Side Effect Profile
- Water retention, increased appetite (MK-677); minimal from BPC-157
- Insulin resistance, joint pain, carpal tunnel, elevated cancer risk
- Minimal documented side effects
- Stack side effects are dose-dependent and reversible; GH carries higher metabolic and oncological risks